New Avenues for the Treatment of Huntington’s Disease
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Huntington’s disease (HD) is a neurodegenerative disorder caused by a CAG expansion in the HD gene. The disease is characterized by neurodegeneration, particularly in the striatum and cortex. The first symptoms usually appear in mid-life and include cognitive deficits and motor disturbances that progress over time. Despite being a genetic disorder with a known cause, several mechanisms are thought to contribute to neurodegeneration in HD, and numerous pre-clinical and clinical studies have been conducted and are currently underway to test the efficacy of therapeutic approaches targeting some of these mechanisms with varying degrees of success. Although current clinical trials may lead to the identification or refinement of treatments that are likely to improve the quality of life of those living with HD, major efforts continue to be invested at the pre-clinical level, with numerous studies testing novel approaches that show promise as disease-modifying strategies. This review offers a detailed overview of the currently approved treatment options for HD and the clinical trials for this neurodegenerative disorder that are underway and concludes by discussing potential disease-modifying treatments that have shown promise in pre-clinical studies, including increasing neurotropic support, modulating autophagy, epigenetic and genetic manipulations, and the use of nanocarriers and stem cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366 · cited 1×
“Since the discovery of the mutation responsible for HD [11], much has been learned regarding the mechanisms that underlie the specific neurodegeneration characteristic of this disease [30].”
BackgroundMangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347 · cited 2×
“Furthermore, the negative regulator of macroautophagy, mammalian target of rapamycin (mTOR), has been shown to be sequestered (and subsequently inhibited) within mHTT aggregates, leading to increased levels of macroautophagy [92].”
BackgroundMethodMetabolic control through the PGC-1 family of transcription coactivators
Lin, J., Handschin, C., & Spiegelman, B. M. (2005) · Cell Metabolism · doi:10.1016/j.cmet.2005.05.004 · Cited by 2,130 · cited 1×
“In fact, it has been demonstrated that not only does PGC-1α effectively suppress the production of free radicals, but it is also required for adaptive thermogenesis as a co-activator of uncoupling protein 1 (UCP1) [81].”
BackgroundKosicki, M., Tomberg, K., & Bradley, A. (2018) · Nature Biotechnology · doi:10.1038/nbt.4192 · Cited by 1,883
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
Hacein-Bey-Abina, S., Garrigue, A., Wang, G. P., Soulier, J., Lim, A., Morillon, E., Clappier, E., Caccavelli, L., Delabesse, E., Beldjord, K., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35700 · Cited by 1,854 · cited 1×
“Another major problem is the risk of accidental insertional mutagenesis by viral vectors and subsequent tumor formation [290].”
BackgroundFatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways
Grimm, D., Streetz, K. L., Jopling, C. L., Storm, T. A., Pandey, K., Davis, C. R., Marion, P., Salazar, F., & Kay, M. A. (2006) · Nature · doi:10.1038/nature04791 · Cited by 1,677 · cited 1×
“Although shRNAs are generally considered toxic due to the saturation of the miRINA biogenesis pathway [421,422], when compared with siRNAs, shRNAs may be less toxic due to the fewer “off-target” effects and the longer-lasting approach.”
BackgroundSaraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.05.044 · Cited by 1,609
Transport of brain-derived neurotrophic factor across the blood–brain barrier
Pan, W., Banks, W. A., Fasold, M. B., Bluth, J., & Kastin, A. J. (1998) · Neuropharmacology · doi:10.1016/s0028-3908(98)00141-5 · Cited by 1,354
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Gauthier, L. R., Charrin, B. C., Borrell-Pagès, M., Dompierre, J. P., Rangone, H., Cordelières, F. P., De Mey, J., MacDonald, M. E., Leßmann, V., Humbert, S., et al. (2004) · Cell · doi:10.1016/j.cell.2004.06.018 · Cited by 1,178
Regional and progressive thinning of the cortical ribbon in Huntington’s disease
Rosas, H. D., Liu, A. K., Hersch, S., Glessner, M., Ferrante, R. J., Salat, D. H., van der Kouwe, A., Jenkins, B. G., Dale, A. M., & Fischl, B. (2002) · Neurology · doi:10.1212/wnl.58.5.695 · Cited by 1,044
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex of p75NTRand Sortilin
Teng, H. K., Teng, K. K., Lee, R., Wright, S., Tevar, S., Almeida, R. D., Kermani, P., Torkin, R., Chen, Z.-Y., Lee, F. S., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.5123-04.2005 · Cited by 1,013 · cited 1×
“The first problem is the regulation of the amount of BDNF produced locally, as an excess of total BDNF can potentially be deleterious, namely, if the mechanisms of BDNF processing are compromised, leading to the accumulation of increased amounts of pro-BDNF, which is known to have pro-apoptotic functions [289].”
BackgroundCui, L., Jeong, H., Borovecki, F., Parkhurst, C. N., Tanese, N., & Krainc, D. (2006) · Cell · doi:10.1016/j.cell.2006.09.015 · Cited by 1,012
Brain-derived neurotrophic factor in neurodegenerative diseases
Zuccato, C., & Cattaneo, E. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.54 · Cited by 947
Cargo recognition failure is responsible for inefficient autophagy in Huntington’s disease
Martinez-Vicente, M., Talloczy, Z., Wong, E., Tang, G., Koga, H., Kaushik, S., de Vries, R., Arias, E., Harris, S., Sulzer, D., et al. (2010) · Nature Neuroscience · doi:10.1038/nn.2528 · Cited by 885 · cited 1×
“However, the resulting autophagosomes have an impaired ability to recognize their cytosolic target cargo and remain relatively empty, leading to a net imbalance of energy expenditure and protein degradation [93].”
Backgroundp75 and Trk: A two-receptor system
Chao, M. V., & Hempstead, B. L. (1995) · Trends in Neurosciences · doi:10.1016/0166-2236(95)93922-k · Cited by 857 · cited 1×
“BDNF exerts its cellular effects through the actions of two receptors: tropomyosin receptor kinase B (TrkB) and p75 neurotrophin receptor (p75NTR) [102].”
BackgroundGDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Postnatal Developmental Profile of Brain-Derived Neurotrophic Factor in Rat Brain and Platelets
Karege, F., Schwald, M., & Cisse, M. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00529-3 · Cited by 799
The U.S.–Venezuela Collaborative Research Project*, & Wexler, N. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308679101 · Cited by 761
Neurotrophin Signaling Through the P75 Neurotrophin Receptor
Roux, P. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00016-3 · Cited by 717
Targeting Huntingtin Expression in Patients with Huntington’s Disease
Tabrizi, S. J., Leavitt, B. R., Landwehrmeyer, G. B., Wild, E. J., Saft, C., Barker, R. A., Blair, N. F., Craufurd, D., Priller, J., Rickards, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1900907 · Cited by 708 · cited 3×
“Intervention (Mechanism) CT Identifier Clinical Trial Stage Phase Allocation Masking Population Period Genetic Manipulations Drug: RO7234292 (RG 6042, IONIS-HTTRx) intrathecal injection NCT03842969 An Open-Label Extension Study to Evaluate Long-Term Safety and Tolerability of RO7234292 (RG6042) in Huntington’s Disease…”
BackgroundMethodIdentification of Genetic Factors that Modify Clinical Onset of Huntington’s Disease
Lee, J.-M., Wheeler, V. C., Chao, M. J., Vonsattel, J. P. G., Pinto, R. M., Lucente, D., Abu-Elneel, K., Ramos, E. M., Mysore, J. S., Gillis, T., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.003 · Cited by 655 · cited 1×
“occurs at a median of 18 years after symptom onset, with infections, specifically aspiration pneumonia, being the most common cause of death [5,6].”
BackgroundLee (2019) · doi:10.1038/s12276-019-0299-y · Cited by 635
Weydt, P., Pineda, V. V., Torrence, A. E., Libby, R. T., Satterfield, T. F., Lazarowski, E. R., Gilbert, M. L., Morton, G. J., Bammler, T. K., Strand, A. D., et al. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.10.004 · Cited by 562
Mechanisms of deep brain stimulation
Herrington, T. M., Cheng, J. J., & Eskandar, E. N. (2016) · Journal of Neurophysiology · doi:10.1152/jn.00281.2015 · Cited by 551 · cited 1×
“It is thought that activation of the stimulated area, with concomitant inhibition of the surrounding area, increases the frequency of action potentials in the area of interest [252].”
BackgroundTerman, A., Kurz, T., Navratil, M., Arriaga, E. A., & Brunk, U. T. (2010) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2598 · Cited by 490 · cited 2×
“These impairments in macroautophagy also lead to a build-up of intralysosomal lipofuscin, which interferes with the ability of the lysosomes to clear autophagic cargo [88].”
BackgroundNeuropsychiatric aspects of Huntington’s disease.
Paulsen, J. S. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.3.310 · Cited by 486 · cited 1×
“The pathophysiology of this symptom is likely related to the degeneration of striatal circuits involving the frontal lobe as well as the ventral anterior and the medial dorsal nuclei of the thalamus [198].”
BackgroundTetrabenazine as antichorea therapy in Huntington disease: A randomized controlled trial
Huntington Study Group (2006) · Neurology · doi:10.1212/01.wnl.0000198586.85250.13 · Cited by 471
Effective gene therapy with nonintegrating lentiviral vectors
Yáñez-Muñoz, R. J., Balaggan, K. S., MacNeil, A., Howe, S. J., Schmidt, M., Smith, A. J., Buch, P., MacLaren, R. E., Anderson, P. N., Barker, S. E., et al. (2006) · Nature Medicine · doi:10.1038/nm1365 · Cited by 460 · cited 1×
“To overcome these problems, new adeno-associated viral vectors lacking pathogenicity and immunogenicity as well as nontoxic viral systems [291,292] are currently being investigated.”
BackgroundDuan, W., Guo, Z., Jiang, H., Ware, M., Li, X.-J., & Mattson, M. P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0536856100 · Cited by 428 · cited 1×
“Although it is possible to increase BDNF levels with dietary interventions [109,273] or through environmental enrichment [274,275] and physical activity [113,276,277], here, we focus on the direct up-regulation of this neurotrophin through protein infusion, genetic approaches, and pharmacological strategies.”
BackgroundHuntingtin functions as a scaffold for selective macroautophagy
Rui, Y.-N., Xu, Z., Patel, B., Chen, Z., Chen, D., Tito, A., David, G., Sun, Y., Stimming, E. F., Bellen, H. J., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3101 · Cited by 423 · cited 1×
“It is hypothesized that the expanded polyglutamine tract on mHTT may be responsible for the dysregulation of these processes [94].”
BackgroundBaquet, Z. C., Gorski, J. A., & Jones, K. R. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.3920-03.2004 · Cited by 414
Potential function for the Huntingtin protein as a scaffold for selective autophagy
Ochaba, J., Lukacsovich, T., Csikos, G., Zheng, S., Margulis, J., Salazar, L., Mao, K., Lau, A. L., Yeung, S. Y., Humbert, S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420103111 · Cited by 308 · cited 1×
“While its function has not been entirely elucidated, it has been proposed to play critical roles in several cellular events such as protein trafficking, transport of vesicles, and selective autophagy [12,13].”
BackgroundIntraneuronal dopamine-quinone synthesis: a review
Sulzer, D., & Zecca, L. (1999) · Neurotoxicity Research · doi:10.1007/bf03033289 · Cited by 284
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
McBride, J. L., Pitzer, M. R., Boudreau, R. L., Dufour, B., Hobbs, T., Ojeda, S. R., & Davidson, B. L. (2011) · Molecular Therapy · doi:10.1038/mt.2011.219 · Cited by 247 · cited 1×
“Of note, the beneficial effects of RNAi-based therapies can also be translated to larger HD animal models, including minipigs and rhesus macaques [236,419].”
BackgroundThe Energetics of Huntington's Disease
Browne, S. E., & Beal, M. F. (2004) · Neurochemical Research · doi:10.1023/b:nere.0000014824.04728.dd · Cited by 240
Zuccato, C., Marullo, M., Conforti, P., MacDonald, M. E., Tartari, M., & Cattaneo, E. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2007.00111.x · Cited by 231
Imam, S. Z., Zhou, Q., Yamamoto, A., Valente, A. J., Ali, S. F., Bains, M., Roberts, J. L., Kahle, P. J., Clark, R. A., & Li, S. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.1833-10.2011 · Cited by 214 · cited 1×
“In Parkinson’s disease, Abl levels, as well as Lewy bodies (inclusions primarily containing aggregated alpha-synuclein), are elevated in nigrostriatal regions [222,223], and the inhibition of Abl has resulted in increased survival of dopaminergic neurons in Parkinson’s disease models [223].”
BackgroundRüb, U., Seidel, K., Heinsen, H., Vonsattel, J. P., den Dunnen, W. F., & Korf, H. W. (2016) · Brain Pathology · doi:10.1111/bpa.12426 · Cited by 206 · cited 1×
“With this increase in the number of CAG repeats (which results in an extended polyglutamine expansion in the N-terminal region of the protein), HTT becomes prone to misfolding and subsequent formation of insoluble aggregates that are often found postmortem both in the nucleus (forming neuronal intranuclear inclusions,…”
BackgroundCognitive disorders and neurogenesis deficits in Huntington’s disease mice are rescued by fluoxetine
Grote, H. E., Bull, N. D., Howard, M. L., Van Dellen, A., Blakemore, C., Bartlett, P. F., & Hannan, A. J. (2005) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2005.04365.x · Cited by 179
Evers, M. M., Miniarikova, J., Juhas, S., Vallès, A., Bohuslavova, B., Juhasova, J., Skalnikova, H. K., Vodicka, P., Valekova, I., Brouwers, C., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.06.021 · Cited by 168 · cited 1×
“Of note, the beneficial effects of RNAi-based therapies can also be translated to larger HD animal models, including minipigs and rhesus macaques [236,419].”
BackgroundLonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1112-3 · Cited by 152
Ubiquilins regulate autophagic flux through mTOR signalling and lysosomal acidification
Şentürk, M., Lin, G., Zuo, Z., Mao, D., Watson, E., Mikos, A. G., & Bellen, H. J. (2019) · Nature Cell Biology · doi:10.1038/s41556-019-0281-x · Cited by 124 · cited 1×
“Indeed, ubiquilins have also been shown to regulate autophagic flux by modulating mTOR signaling and lysosomal acidification [341].”
BackgroundMealer, R. G., Murray, A. J., Shahani, N., Subramaniam, S., & Snyder, S. H. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.536912 · Cited by 124
Hathorn, T., Snyder-Keller, A., & Messer, A. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.017 · Cited by 123
Distinct cognitive profiles of cortical and subcortical dementia in advanced illness
Paulsen, J. S., Butters, N., Sadek, J. R., Johnson, S. A., Salmon, D. P., Swerdlow, N. R., & Swenson, M. R. (1995) · Neurology · doi:10.1212/wnl.45.5.951 · Cited by 97 · cited 1×
“As stated above, the cognitive deficits seen in HD are thought to be primarily subcortical and include decreased processing speed, poor attention, poor problem-solving abilities, and poor memory retrieval [188].”
BackgroundBusse, M., Quinn, L., Debono, K., Jones, K., Collett, J., Playle, R., Kelly, M., Simpson, S., Backx, K., Wasley, D., et al. (2013) · Journal of Neurologic Physical Therapy · doi:10.1097/npt.0000000000000016 · Cited by 97
A controlled trial of idebenone in Huntington's disease
Ranen, N. G., Peyser, C. E., Coyle, J. T., Bylsma, F. W., Sherr, M., Day, L., Folstein, M. F., Brandt, J., Ross, C. A., & Folstein, S. E. (1996) · Movement Disorders · doi:10.1002/mds.870110510 · Cited by 97
Systematic review of pharmacological treatments for depressive symptoms in Huntington’s disease
Moulton, C. D., Hopkins, C. W. P., & Bevan‐Jones, W. R. (2014) · Movement Disorders · doi:10.1002/mds.25980 · Cited by 49
MicroRNA-27a reduces mutant hutingtin aggregation in an in vitro model of Huntington's disease
Ban, J.-J., Chung, J.-Y., Lee, M., Im, W., & Kim, M. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.05.040 · Cited by 36
Cited by
Adamu, A., Li, S., Gao, F., & Xue, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1347987 · Cited by 564
The role of PI3K signaling pathway in Alzheimer’s disease
Pan, J., Yao, Q., Wang, Y., Chang, S., Li, C., Wu, Y., Shen, J., & Yang, R. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1459025 · Cited by 89
Gao, L., Wang, J., & Bi, Y. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s549893 · Cited by 52
Metadata
- Authors
- Kim, A., Lalonde, K., Truesdell, A., Gomes Welter, P., Brocardo, P. S., Rosenstock, T. R., & Gil-Mohapel, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-08-04
- Volume
- 22
- Issue
- 16
- Pages
- 8363
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W3187326368
- Cited by
- 191
- References
- 53
- FWCI
- 11.67
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.